Revive Therapeutics Ltd.
RVV
CNSX
| 12/31/2024 | 09/30/2024 | 06/30/2024 | 03/31/2024 | 12/31/2023 | |
|---|---|---|---|---|---|
| Net Income | -260.50K | -346.40K | -1.89M | -1.39M | -566.40K |
| Total Depreciation and Amortization | 0.00 | 0.00 | 100.00 | 100.00 | 100.00 |
| Total Amortization of Deferred Charges | -- | -- | -- | -- | -- |
| Total Other Non-Cash Items | 7.10K | 4.20K | 1.69M | 119.00K | 29.10K |
| Change in Net Operating Assets | 97.90K | -2.50K | -1.30K | 56.20K | -112.00K |
| Cash from Operations | -155.40K | -344.60K | -201.90K | -1.21M | -649.30K |
| Capital Expenditure | -- | -- | -- | -- | -- |
| Sale of Property, Plant, and Equipment | -- | -- | -- | -- | -- |
| Cash Acquisitions | -- | -- | -- | -- | -- |
| Divestitures | -- | -- | -- | -- | -- |
| Other Investing Activities | 0.00 | -22.00K | 29.20K | -29.70K | -- |
| Cash from Investing | 0.00 | -22.00K | 29.20K | -29.70K | -- |
| Total Debt Issued | -- | -- | -- | -- | -- |
| Total Debt Repaid | 0.00 | -25.80K | -78.80K | -38.80K | -38.80K |
| Issuance of Common Stock | -- | -- | 84.10K | 2.02M | -- |
| Repurchase of Common Stock | -- | -- | -- | -- | -- |
| Issuance of Preferred Stock | -- | -- | -- | -- | -- |
| Repurchase of Preferred Stock | -- | -- | -- | -- | -- |
| Total Dividends Paid | -- | -- | -- | -- | -- |
| Other Financing Activities | 0.00 | 25.80K | -45.30K | 38.80K | 38.80K |
| Cash from Financing | 0.00 | 0.00 | -29.20K | 1.50M | 0.00 |
| Foreign Exchange rate Adjustments | -- | -- | -- | -- | -- |
| Miscellaneous Cash Flow Adjustments | -- | -- | -- | -- | -- |
| Net Change in Cash | -155.40K | -366.60K | -201.90K | 252.90K | -649.30K |